Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Lung Transplant
•
Antifibrotic
•
CLAD
Do you use antifibrotics in patients with restrictive allograft syndrome post lung transplant?
Related Questions
What are your top takeaways from ISHLT 2024?
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
Do you treat A0B1 rejection noted on surveillance bronchoscopy in a patient less than one year post lung transplant?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
What policies do you take regarding legalized recreational marijuana or medical marijuana use in transplant patients?
Do you routinely perform a pre-extubation bronchoscopy for secretion clearance during the index hospitalization in patients following lung transplantation?
What agents do you utilize for mucociliary clearance during the index hospitalization of patients post lung transplant?
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
Do you use bronchodilator response to distinguish between asthma, COPD, or asthma-COPD overlap?
Do shorter door-to-balloon (D2B) times impact outcomes in STEMI, if it's already less than 90 minutes, and to what degree (i.e., 30 vs 60 minutes would have a more significant impact)?
